Corcept Therapeutics Incorporated filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 3, 2026, reporting third-quarter net product revenue of $340,472 thousand and net income of $126,778 thousand.

Key Highlights

  • Q3 2026 net product revenue: $340,472 thousand, up from $207,638 thousand in Q3 2025.
  • Q3 2026 net income: $126,778 thousand, compared to $19,668 thousand in the same quarter of 2025.
  • Nine-month net product revenue: $761,522 thousand for the nine months ended September 30, 2026, versus $559,282 thousand for the same period in 2025.
  • Diluted net income per common share: $1.01 for Q3 2026, compared to $0.16 for Q3 2025.
  • Total assets: $1,034,027 thousand as of September 30, 2026, up from $836,651 thousand at December 31, 2025.
  • Shares outstanding: 109,443,109 shares of common stock as of October 22, 2026.
  • Operating cash flow: $159,662 thousand for the nine months ended September 30, 2026.

Corcept Therapeutics Q3 2026 Financial Results: Revenue and Income Detail

According to the filing, Corcept Therapeutics Incorporated (NASDAQ:CORT) reported net product revenue of $340,472 thousand for the three months ended September 30, 2026, compared to $207,638 thousand for the three months ended September 30, 2025. For the nine months ended September 30, 2026, net product revenue totaled $761,522 thousand, versus $559,282 thousand for the comparable prior-year period. Total operating expenses for Q3 2026 were $225,748 thousand, leaving income from operations of $114,724 thousand, against $10,219 thousand in Q3 2025.

The company disclosed net income of $126,778 thousand for the third quarter of 2026, which included an income tax benefit of $6,471 thousand. Basic net income per common share was $1.17 and diluted net income per common share was $1.01 for Q3 2026, based on weighted-average diluted shares outstanding of 123,201 thousand. For the nine months ended September 30, 2026, net income totaled $138,004 thousand, with diluted net income per common share of $1.13.

The condensed consolidated balance sheet as of September 30, 2026, reflected total assets of $1,034,027 thousand, compared to $836,651 thousand at December 31, 2025. Total stockholders' equity stood at $833,740 thousand at the end of the quarter. The filing reported net cash provided by operating activities of $159,662 thousand for the nine months ended September 30, 2026. Stock-based compensation for the same nine-month period was $81,902 thousand. The company repurchased common stock totaling $5,745 thousand under its Stock Repurchase Program during the nine months ended September 30, 2026, compared to $172,915 thousand in the prior-year period.

What Was Disclosed

Corcept Therapeutics filed a Form 10-Q for the quarter ended September 30, 2026, disclosing unaudited financial statements including income, balance sheet, and cash flow data, along with management's discussion and risk factors.